When to recommend allogeneic transplant in multiple myeloma

References

• McCarthy PL, Jr, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013;19:1116–1123.
   PubMed Web of Science ®Google Scholar
• Kumar S, Zhang MJ, Li P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011;118:1979–1988.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood 2014;124:328–333.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant 2013;48:294–300.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 2014;124: 882–890.
   PubMed Web of Science ®Google Scholar
• Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol 2010;148:373–385.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Khan H, Thall PF, et al. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant 2013;19: 1453–1458.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Martin PJ, Storb RF, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 2014;124:287–295.
   PubMed Web of Science ®Google Scholar
• Donato ML, Siegel DS, Vesole DH, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant 2014;20:1211–1216.
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–3480.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591–3593.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011;29:3016–3022.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Iacobelli S, Bjorkstrand B, et al. .Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055–5063.
   PubMed Web of Science ®Google Scholar
• Stefan Knop S, Peter Liebisch P, Hebart H, et al. Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma. Blood 2014;124:43;meeting abstract.
   Google Scholar
• Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–1120.
   PubMed Web of Science ®Google Scholar
• Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011;117:6721–6727.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–1203.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012;119:6219–6225; quiz 6399.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2013;6:2.
   PubMed Web of Science ®Google Scholar
• Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013;48:562–567.
   PubMed Web of Science ®Google Scholar
• Sahebi F, Iacobelli S, Biezen AV, et al. Comparison of up- front tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 2015;50:802–807.
   PubMed Web of Science ®Google Scholar
• Nishihori T, Ochoa-Bayona JL, Kim J, et al. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant 2013;48:1179–1184.
   PubMed Web of Science ®Google Scholar
• Karlin L, Arnulf B, Chevret S, et al. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy. Bone Marrow Transplant 2011;46:250–256.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Khan H, Orlowski RZ, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012;87:272–276.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Rotta M, Storer B, et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012;47:1312–1317.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012;18:617–626.
   PubMed Web of Science ®Google Scholar
• Wirk B, Byrne M, Dai Y, et al. Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation. J Clin Med Res 2013;5:174–184.
   PubMedGoogle Scholar
• Kroger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant 2013;48:403–407.
   PubMed Web of Science ®Google Scholar
• Sahebi F, Shen Y, Thomas SH, et al. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 2013;160:199–206.
   PubMed Web of Science ®Google Scholar
• Vekemans MC, Michaux L, Van Den Neste E, et al. Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma. Br J Haematol 2014;166:616–618.
   PubMed Web of Science ®Google Scholar
• Auner HW, Szydlo R, van Biezen A, et al. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013;48:1395–1400.
   PubMed Web of Science ®Google Scholar
• Freytes CO, Vesole DH, LeRademacher J, et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant 2014;49:416–421.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Crocchiolo R, Boher JM, et al. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. Eur J Haematol 2012;88: 497–503.
   PubMed Web of Science ®Google Scholar
• Kroger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013;19:398–404.
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, El-Cheikh J, et al. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp Hematol 2013;41:1008–1015.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Krishnan A. Allogeneic transplantation in multiple myeloma. Expert Rev Hematol 2014;7:79–90.
   PubMed Web of Science ®Google Scholar
• Passera R, Pollichieni S, Brunello L, et al. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. Biol Blood Marrow Transplant 2013;19:940–948.
   PubMed Web of Science ®Google Scholar
• Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–3594.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209–216.
   PubMed Web of Science ®Google Scholar
• Salit RB, Bishop MR. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review. Clin Lymphoma Myeloma Leuk 2011;11:247–252.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Crocchiolo R, Furst S, et al. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am J Hematol 2013;88:370–374.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Giralt S, Koehne G. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any? Curr Hematologic Malig Rep 2013;8:284–290.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Crocchiolo R, Boher JM, et al. Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved? Leuk Lymphoma 2012;53:1630–1632.
   PubMed Web of Science ®Google Scholar
• Mohty M, Attal M, Marit G, et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005;35: 165–169.
   PubMed Web of Science ®Google Scholar
• Coman T, Bachy E, Michallet M, et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica 2013;98:776–783.
   PubMed Web of Science ®Google Scholar
• Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521–4530.
   PubMed Web of Science ®Google Scholar